IntelliPharmaCeutics International (IntelliPharmaCeutics International) Accounts Receivable : $0.00 Mil (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. IntelliPharmaCeutics International's accounts receivables for the quarter that ended in Aug. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. IntelliPharmaCeutics International's Days Sales Outstanding for the quarter that ended in Aug. 2023 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. IntelliPharmaCeutics International's Net-Net Working Capital per share for the quarter that ended in Aug. 2023 was $-0.42.

IntelliPharmaCeutics International Accounts Receivable Historical Data

The historical data trend for IntelliPharmaCeutics International's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Accounts Receivable Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Accounts Receivable

Get a 7-Day Free Trial

0.24

0.18

0.07

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Accounts Receivable	Get a 7-Day Free Trial															-	-	0.21	0.33	-

IntelliPharmaCeutics International Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

IntelliPharmaCeutics International Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

IntelliPharmaCeutics International's Days Sales Outstanding for the quarter that ended in Aug. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.069	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), IntelliPharmaCeutics International's accounts receivable are only considered to be worth 75% of book value:

IntelliPharmaCeutics International's Net-Net Working Capital Per Share for the quarter that ended in Aug. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.4	+	0.75 * 0	+	0.5 * 0	-	14.442
-	0	-	0)	/	33.0927
=	-0.42

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

IntelliPharmaCeutics International Accounts Receivable Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.